Nanoparticles as tool for enhanced ophthalmic delivery of vancomycin: a multidistrict-based microbiological study, solid lipid nanoparticles formulation and evaluation

Drug Development and Industrial Pharmacy

Volumn 42, Issue 11, 2016, Pages 1752-1762

  Yousry, Carol ^a   Fahmy, Rania Hassan ^a   Essam, Tamer ^a   El laithy, Hanan M ^a,b   Elkheshen, Seham A ^a,c  

^a CAIRO UNIVERSITY   (Egypt)

^b October University for Modern Sciences and Arts   (Egypt)

^c Future University in Egypt   (Egypt)

Author keywords

Egypt; multi district microbiological survey; ocular infection; solid lipid nanoparticles; vancomycin

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; AZTREONAM; CEFOPERAZONE; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GELUCIRE; GENTAMICIN; GUANOSINE DIPHOSPHATE; GUANOSINE PHOSPHATE; IMIPENEM; LEVOFLOXACIN; METICILLIN; MEZLOCILLIN; NOVOBIOCIN; OIL; PIPERACILLIN; POLYVINYL ALCOHOL; SOLID LIPID NANOPARTICLE; SULTAMICILLIN; TRIPALMITIN; VANCOMYCIN; WATER; EMULSION; LIPID; NANOPARTICLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG FORMULATION; DRUG PENETRATION; EVAPORATION; INTRAOCULAR DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; STAPHYLOCOCCUS; ZETA POTENTIAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG DELIVERY SYSTEM; EMULSION; EYE; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MICROBIOLOGY; PROCEDURES; ULTRASOUND;

DRUG DELIVERY SYSTEMS; EMULSIONS; EYE; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPIDS; MICROBIOLOGICAL PHENOMENA; NANOPARTICLES; PARTICLE SIZE; POLYVINYL ALCOHOL; SONICATION; VANCOMYCIN;

EID: 84965000059     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2016.1171335     Document Type: Article

References (40)

1. K.R.Wilhelmus, T.J.Liesegang, M.S.Osato, D.B.Jones Cumitech 13A, Laboratory diagnosis of ocular infections. Washington, DC:American Society for Microbiology; 1994:9–20.
2. F.S.Southwick Eye, ear, nose, and throat infections. In:F.Southwick, ed. Infectious diseases a clinical short course. 3rd edn. New York:McGraw-Hill Education; 2014:125–32.
3. F.Schaefer, O.Bruttin, L.Zografos, Y.Guex-Crosier Bacterial keratitis:a prospective clinical and microbiological study. Br J Ophthalmol 2001;85:842–7.
4. R.P.F.Cheung, J.T.Dipiro Vancomycin:an update. Pharmacotherapy 1986;6:153–69.
5. A.Mohammed Fayaz, M.Girilal, S.A.Mahdy,. Vancomycin bound biogenic gold nanoparticles:a different perspective for development of anti VRSA agents. Process Biochem 2011;46:636–41.
6. A.C.Moffat, M.D.Osselton, B.Widdop. Clarke's analysis of drugs and poisons. London, UK:Pharmaceutical Press; 2005.
7. M.M.D.C.Vila, R.M.D.Oliveira, M.M.Gonçalves, M.Tubino Analytical methods for vancomycin determination in biological fluids and in pharmaceuticals. Quim Nov 2007;30:395–9.
8. E.Gavini, P.Chetoni, M.Cossu,. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method:in vitro/in vivo studies. Eur J Pharm Biopharm 2004;57:207–12.
9. W.Hachicha, L.Kodjikian, H.Fessi Preparation of vancomycin microparticles:importance of preparation parameters. Int J Pharm 2006;324:176–84.
10. J.Araújo, E.Gonzalez, M.A.Egea,. Nanomedicines for ocular NSAIDs:safety on drug delivery. Nanomedicine 2009;5:394–401.
11. I.P.Kaur, A.Garg, A.K.Singla, D.Aggarwal Vesicular systems in ocular drug delivery:an overview. Int J Pharm 2004;269:1–14.
12. G.Y.Liu, A.Omri, L.Sande Liposomal vancomycin for the treatment of MRSA infections; 2011. Available from:http://www.google.com/patents/WO2012149116A2?cl=en.
13. A.Attama, S.Reichl, C.C.Müller-Goymann Diclofenac sodium delivery to the eye:in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008;355:307–13.
14. M.Ghadiri, S.Fatemi, A.Vatanara,. Loading hydrophilic drug in solid lipid media as nanoparticles:statistical modeling of entrapment efficiency and particle size. Int J Pharm 2012;424:128–37.
15. G.P.Hansraj, S.K.Singh, P.Kumar Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential. Int J Biol Macromol 2015;81:467–76.
16. B.Shah, D.Khunt, H.Bhatt,. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles:effect on formulation and characterization parameters. Eur J Pharm Sci 2015;78:54–66.
17. Y.-I.Jeong, H.-S.Na, D.-H.Seo,. Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity. Int J Pharm 2008;352:317–23.
18. S.A.Wissing, O.Kayser, R.H.Müller Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257–72.
19. M.Nabi-meibodi, A.Vatanara, A.Rouholamini The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method. Colloids Surf B Biointerfaces 2013;112:408–14.
20. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 19th Informational Suppl CLSI Doc M100-S19. Wayne, PA:CLSI; 2009.
21. M.M.Ismail, T.M.Essam, A.F.Mohamed, F.E.Mourad Screening for the antimicrobial activities of alcoholic and aqueous extracts of some common species in Egypt. Int J Microbiol Res 2012;3:200–7.
22. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 21st Informational Suppl CLSI Doc M100-S21. Wayne, PA:CLSI; 2011.
23. D.Hou, C.Xie, K.Huang, C.Zhu The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003;24:1781–5.
24. D.Y.Aksoy, M.D.Tanriover, S.Unal Antimicrobial resistance:preventable or inevitable? In:I.M.Gould, J.W.V.D.MeerJW van der, eds. Antibiotic policies:fighting resistance. New York:Springer Science + Business Media, LLC; 2008:113–34.
25. P.Aksungur, M.Demirbilek, E.B.Denkbas,. Development and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery:cellular toxicity, uptake, and kinetic studies. J Control Release 2011;151:286–94.
26. W.Mehnert, K.Mader. Solid lipid nanoparticles:production, characterization and applications. Adv Drug Deliv Rev 2001;47:165–96.
27. K.Westesen, H.J.Michel Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 1996;129:159–73.
28. G.Abdelbary, R.H.Fahmy Diazepam-loaded solid lipid nanoparticles:design and characterization. AAPS PharmSciTech 2009;10:211–19.
29. A.Manosroi, P.Wongtrakul, J.Manosroi,. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf B Biointerfaces 2003;30:129–38.
30. S.Chibowski, M.Paszkiewicz, M.Krupa Investigation of the influence of the polyvinyl alcohol adsorption on the electrical properties of Al2O3 – solution interface, thickness of the adsorption layers of PVA. Powder Technol 2000;107:251–5.
31. D.H.Mobarak, S.Salah, S.A.Elkheshen Formulation of ciprofloxacin hydrochloride loaded biodegradable nanoparticles:optimization of technique and process variables. Pharm Dev Technol 2013;19:891–900.
32. R.H.Müller, G.M.Vuleta, A.B.Kovă, C.M.Keck Physicochemical and engineering aspects solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants:preparation, characterization and physical stability investigation. Colloids Surf A Physicochem Eng Asp 2014;444:15–25.
33. M.Uner, G.Yener Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2:289–300.
34. A.S.Guinedi, N.D.Mortada, S.Mansour, R.M.Hathout Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm 2005;306:71–82.
35. V.Jenning, S.Gohla Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int J Pharm 2000;196:219–22.
36. R.H.Müller, K.Mäder, S.Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77.
37. R.M.Moosa, Y.E.Choonara, L.C.D.Toit,. In vivo evaluation and in-depth pharmaceutical characterization of a rapidly dissolving solid ocular matrix for the topical delivery of timolol maleate in the rabbit eye model. Int J Pharm 2014;466:296–306.
38. P.Zakeri-milani, B.D.Loveymi, M.Jelvehgari,. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 2013;103:174–81.
39. C.Vitorino, F.A.Carvalho, A.J.Almeida, J.J.Sousa, Pais AACC. The size of solid lipid nanoparticles:an interpretation from experimental design. Colloids Surf B Biointerfaces 2011;84:117–30.
40. H.Gupta, B.Pharm, M.Pharm,. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2010;6:324–33.